Efficacy of contingency management for cocaine dependence treatment: A review of the evidence

Current Drug Abuse Reviews

Volumn 5, Issue 4, 2012, Pages 320-331

  Schierenberg, Alwin ^a   van Amsterdam, Jan ^b   van den Brink, Wim ^b,c   Goudriaan, Anna E ^b,c,d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c AMSTERDAM INSTITUTE FOR ADDICTION RESEARCH   (Netherlands)

^d Arkin Mental Health Care   (Netherlands)

Author keywords

Abstinence; Cocaine dependence; Contingency management; Pharmacotherapy; Treatment retention; Voucher based reinforcement

Indexed keywords

AMFEBUTAMONE; ATOMOXETINE; CITALOPRAM; CYCLOSERINE; DEXAMPHETAMINE; DISULFIRAM; FLUOXETINE; LEVODOPA; LISDEXAMFETAMINE; MEMANTINE; MODAFINIL; NALTREXONE; ONDANSETRON; PLACEBO; SEROTONIN; TRYPTOPHAN;

ARTICLE; BEHAVIOR THERAPY; COCAINE DEPENDENCE; COGNITIVE THERAPY; CONTINGENCY TABLE; CONTROLLED STUDY; FACILITATION; HUMAN; INSTRUMENTAL CONDITIONING; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PSYCHOPHARMACOTHERAPY; REIMBURSEMENT; REINFORCEMENT; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW;

EID: 84873104836     PISSN: 18744737     EISSN: 18744745     Source Type: Journal    
DOI: 10.2174/1874473711205040006     Document Type: Article

References (56)

1. van Amsterdam J, Opperhuizen A, Koeter M, van den Brink W. Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population. Eur Addict Res 2010; 16(4): 202-207.
2. UNODC. World Drug Report. United Nations Office on Drugs and Crime; May 2011; pp. 1-272. Report No.: E.11.XI.10.
3. EMCDDA. 2011 Annual report on the state of the drugs problem in the European Union. European Monitoring Centre for Drugs and Drug Addiction: Lisbon 2011.
4. van den Brink W. Evidence-based Pharmacological Treatment of Substance use Disorders and Pathological Gambling. Curr Drug Abuse Rev 2012; 5(1): 3-31.
5. Knapp WP, Soares BGO, Farrel M, Lima MS. Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders. Cochrane Database Syst Rev 2007; (3): CD003023.
6. Prendergast M, Podus D, Finney J, Greenwell L, Roll J. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction 2006; 101(11): 1546-1460.
7. Lussier JP, Heil SH, Mongeon JA, Badger GJ, Higgins ST. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction 2006; 101(2): 192-203.
8. Carroll KM, Rounsaville BJ. A perfect platform: combining contingency management with medications for drug abuse. Am J Drug Alcohol Abuse 2007; 33(3): 343-365.
9. Stitzer ML, Vandrey R. Contingency management: utility in the treatment of drug abuse disorders. Clin Pharmacol Ther 2008; 83(4): 644-647.
10. National Institute on Drug Abuse (NIDA). Principles of Drug Addiction Treatment. NIH publication 1999.
11. R. Treatment for Stimulant Use Disorders Treatment Improvement Protocol (TIP) Series. 1999.
12. Stine SM, Burns B, Kosten T. Methadone dose for cocaine abuse. 9th ed. US: American Psychiatric Ass US 1991
13. Stine SM, Freeman M, Burns B, Charney DS, Kosten TR. Effect of methadone dose on cocaine abuse in a methadone program. Am J Addict 1992; 1(4): 294-303.
14. Stitzer ML, Iguchi MY, Felch LJ. Contingent take-home incentive: effects on drug use of methadone maintenance patients. J Consult Clin Psychol. 1992 Dec;60(6):927-934.
15. Petry NM, Tedford J, Austin M, Nich C, Carroll KM, Rounsaville BJ. Prize reinforcement contingency management for treating cocaine users: how low can we go, and with whom? Addiction 2004; 99(3): 349-360.
16. Higgins ST, Budney AJ, Bickel WK, Hughes JR, Foerg F, Badger G. Achieving cocaine abstinence with a behavioral approach. Am J Psychiatry 1993; 150(5): 763-769.
17. Higgins ST, Budney AJ, Bickel WK, Badger GJ, Foerg FE, Ogden D. Outpatient behavioral treatment for cocaine dependence: One-year outcome. Exp Clin Psychopharmac: Am Psychol Assoc 1995;3(2): 205-212.
18. Roozen HG, Boulogne JJ, van Tulder MW, van den Brink W, De Jong CAJ, Kerkhof AJFM. A systematic review of the effectiveness of the community reinforcement approach in alcohol, cocaine and opioid addiction. Drug Alcohol Depend 2004; 74(1): 1-13.
19. Higgins ST, Delaney DD, Budney AJ, et al. A behavioral approach to achieving initial cocaine abstinence. Am J Psychiatry 1991; 148(9): 1218-1224.
20. Garcia-Rodriguez O, Secades-Villa R, Higgins ST, et al. Effects of voucher-based intervention on abstinence and retention in an outpatient treatment for cocaine addiction: a randomized controlled trial. Exp Clin Psychopharmacol 2009; 17(3): 131-138.
21. Secades-Villa R, Garcia-Rodriguez O, Garcia-Fernandez G, Sanchez-Hervas E, Fernandez-Hermida JR, Higgins ST. Community reinforcement approach plus vouchers among cocaine-dependent outpatients: twelve-month outcomes. Psychol Addict Behav 2011; 25(1): 174-179.
22. Secades-Villa R, Garcia-Rodriguez O, Higgins ST, Fernandez-Hermida JR, Carballo JL. Community reinforcement approach plus vouchers for cocaine dependence in a community setting in Spain: Six-month outcomes. J Subst Abuse Treat 2008; 34(2): 202-207.
23. Higgins ST, Budney AJ, Bickel WK, Foerg FE, Donham R, Badger GJ. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry 1994; 51(7): 568-576.
24. Higgins ST, Wong CJ, Badger GJ, Ogden DE, Dantona RL. Contingent reinforcement increases cocaine abstinence during outpatient treatment and 1 year of follow-up. J Consult Clin Psychol 2000; 68(1): 64-72.
25. Garcia-Fernandez G, Secades-Villa R, Garcia-Rodriguez O, et al. Long-term benefits of adding incentives to the community reinforcement approach for cocaine dependence. Eur Addict Res 2011; 17(3): 139-145.
26. Garcia-Fernandez G, Secades-Villa R, Garcia-Rodriguez O, Sanchez-Hervas E, Fernandez-Hermida JR, Higgins ST. Adding voucher-based incentives to community reinforcement approach improves outcomes during treatment for cocaine dependence. Am J Addict 2011; 20(5): 456-461.
27. Schottenfeld RS, Moore B, Pantalon MV. Contingency management with community reinforcement approach or twelve-step facilitation drug counseling for cocaine dependent pregnant women or women with young children. Drug Alcohol Depend 2011; 118(1): 48-55.
28. Higgins ST, Sigmon SC, Wong CJ, et al. Community reinforcement therapy for cocaine-dependent outpatients. archives of general psychiatry. JAMA 2003; 60(10): 1043-1052.
29. N. Drug dependence and addiction, III: Expectation and brain function in drug abuse. Am J Psychiatry 2004; 161(4): 621.
30. Dackis CA, Gold MS. New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci Biobehav Rev 1985; 9(3): 469-477.
31. Schmitz JM, Mooney ME, Moeller FG, Stotts AL, Green C, Grabowski J. Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. Drug Alcohol Depend 2008; 94(1-3): 142-150.
32. Kalivas PW. Neurobiology of Cocaine addiction: implications for new pharmacotherapy. Am J Addict 2007; 16(2): 71-78.
33. Schmitz JM, Lindsay JA, Stotts AL, Green CE, Moeller FG. Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets. Exp Clin Psychopharmacol 2010; 18(3): 238-244.
34. Schmitz JM, Rhoades HM, Elk R, Creson D, Hussein I, Grabowski J. Medication take-home doses and contingency management. Exp Clin Psychopharmacol 1998; 6(2): 162-168.
35. Moeller FG, Schmitz JM, Steinberg JL, et al. Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. Am J Drug Alcohol Abuse 2007; 33(3): 367-378.
36. Jones HE, Johnson RE, Bigelow GE, Silverman K, Mudric T, Strain EC. Safety and efficacy of L-tryptophan and behavioral incentives for treatment of cocaine dependence: a randomized clinical trial. Am J Addict 2004; 13(5): 421-437.
37. Bisaga A, Aharonovich E, Cheng WY, et al. A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period. Drug Alcohol Depend 2010; 111(1-2): 97-104.
38. Schmitz JM, Lindsay JA, Green CE, Herin DV, Stotts AL, Gerard Moeller F. High-dose naltrexone therapy for cocaine-alcohol dependence. Am J Addict 2009; 18(5): 356-362.
39. Shoptaw S, Watson DW, Reiber C, et al. Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). Addiction 2005; 100 Suppl 1: 78-90.
40. Mooney ME, Schmitz JM, Moeller FG, Grabowski J. Safety, tolerability and efficacy of levodopa-carbidopa treatment forcocaine dependence: two double-blind, randomized, clinical trials. Drug Alcohol Depend 2007; 88(2-3): 214-223.
41. Grabowski JJ, Rhoades HH, Kirby KK, 7. Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate andcocaine dependence: two placebo-controlled double-blind trials. J Clin Psychopharmacol 1995; 15(3): 163-174.
42. Fernstrom JD, Wurtman RJ. Brain serotonin content: physiological dependence on plasma tryptophan levels. Science 1971; 173(3992): 149-152.
43. Carroll ME, Lac ST, Asencio M, Kragh R. Intravenous cocaine self-administration in rats is reduced by dietary L-tryptophan. Psychopharmacology (Berl.). 1990;100(3):293-300.
44. McGregor A, Lacosta S, Roberts DC. L-tryptophan decreases the breaking point under a progressive ratio schedule e of intravenous cocaine reinforcement in the rat. Pharmacol. Biochem. Behav 1993; 44(3): 651-655.
45. Maldonado C, Rodríguez-Arias M, Miñarro J, 5. Effect of memantine and CNQX in the acquisition, expression n and reinstatement of cocaine-induced conditioned place preference. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(4): 932-939.
46. Newman JL, Beardsley PM. Effects of memantine, haloperidol, and cocaine on primary and conditioned reinforcement associated with cocaine in rhesus monkeys. Psychopharmacology (Berl.). 2006; 185(2): 142-149.
47. Collins EDE, Vosberg SKS, Foltin RWR, 5. The effects of acute pretreatment with high-dose memantine on the cardiovascular and behavioral effects of cocaine in humans. Exp Clin Psychopharmacol 2007; 15(3): 228-237.
48. Hersh D, Van Kirk JR, Kranzler HR. Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology (Berl.) 1998; 139(1-2): 44-52.
49. Schmitz JM, Stotts AL, Sayre SL, DeLaune KA, Grabowski J. Treatment of cocaine-alcohol dependence with naltrexone and relapse prevention therapy. Am J Addict 2004; 13(4): 333-341.
50. Schmitz JM, Lindsay JA, Green CE, Herin DV, Stotts AL, Moeller FG. High-dose naltrexone therapy for cocain e-alcohol dependence. Am J Addict 2009; 18(5): 356-62.
51. Grassi MCM, Cioce AMA, Nencini PP, 5. Short-term efficacy of Disulfiram or Naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacol Res 2007; 55(2): 117-121.
52. Somaini L, Donnini C, Raggi MA, et al. Promising medications for cocaine dependence treatment. Recent Pat CNS Drug Discov 2011; 6(2): 146-160.
53. Karila L, Reynaud M, Aubin H-J, et al. Pharmacological treatments for cocaine dependence: is there something new? Curr. Pharm. Des 2011; 17(14): 1359-1368.
54. Kampman K. What's new in the treatment of cocaine addiction? Curr Psychiatry Rep 2010; 12: 441-7.
55. Blick SKA, Keating GM. Lisdexamfetamine. Paediatr Drugs 2007; 9(2): 12-35; discussion 136-8
56. Ramsey NFN, van Ree JMJ. Intracerebroventricular naltrexone treatment attenuates acquisition of intravenous cocaine self-administration in rats. Pharmacol. Biochem. Behav 1991; 40(4): 807-810.